Intellia Therapeutics doesn’t need to re-dose patients with a CRISPR gene edited therapy for transthyretin (ATTR) amyloidosis. But new data suggests it could be done.

What if a major transplant surgery could have the same convenience as an outpatient procedure? Surgeons at Northwestern Medicine now have a better idea of the potential benefits after delivering a new kidney without using general anesthesia—and being able to discharge the patient the next day.

Endotronix has secured an FDA approval for its early warning sensor implant to remotely track patients with serious and potentially worsening heart failure.

Eli Lilly is teaming up with OpenAI on a quest to develop new treatments that overcome antimicrobial resistance (AMR).

Terns Pharmaceuticals’ prediction that its shelved metabolic dysfunction-associated steatohepatitis (MASH) drug TERN-501 could be effective against obesity in a combination treatment appears to be playing out, at least preclinically.

At the scientific sessions of the American Diabetes Association, multiple studies were presented showing benefits in Type 2 diabetes through a combination of continuous glucose monitoring and automated insulin pumps.

Just last month, Merck KGaA executives were reassuring analysts that the failure of a phase 3 trial of xevinapant was “unlikely.” Now that worst-case scenario has come to pass. The company will now halt both studies on what was once a key brick in the German pharma’s oncology wall.

GLP-1 drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy work to address obesity—as long as a patient keeps taking them.

Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggests the anti-CD38 antibody could still “transform treatment” of primary immune thrombocytopenia (ITP).

Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability.